Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANXNASDAQ:PEPGNASDAQ:QNCXNASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.88-1.6%$1.94$0.89▼$3.19$54.04M0.18296,965 shs440,976 shsPEPGPepGen$1.53-4.4%$1.73$0.88▼$19.30$50.02M1.42815,995 shs91,085 shsQNCXQuince Therapeutics$1.13-0.3%$1.27$0.51▼$2.45$49.86M0.74248,847 shs43,744 shsSNYRSynergy CHC Corp. (Uplisting)$1.90-1.0%$2.80$0.12▼$10.00$16.29MN/A850,871 shs90,405 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics-1.57%+1.62%-0.53%-10.05%-37.33%PEPGPepGen-4.38%-5.56%+3.38%-16.85%-86.90%QNCXQuince Therapeutics-0.26%+7.62%-16.30%-31.10%+7.11%SNYRSynergy CHC Corp. (Uplisting)-1.04%-19.49%-34.48%-54.76%+189,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics3.0527 of 5 stars3.65.00.00.02.90.80.6PEPGPepGen2.7721 of 5 stars3.23.00.00.02.22.51.3QNCXQuince Therapeutics2.8546 of 5 stars3.63.00.00.02.70.81.3SNYRSynergy CHC Corp. (Uplisting)3.5425 of 5 stars3.80.00.00.03.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.17Buy$8.20336.17% UpsidePEPGPepGen 2.33Hold$10.33575.38% UpsideQNCXQuince Therapeutics 3.29Buy$8.00607.96% UpsideSNYRSynergy CHC Corp. (Uplisting) 3.50Strong Buy$10.00426.32% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, PEPG, GANX, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/25/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $4.003/24/2025QNCXQuince TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.003/17/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025GANXGain TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform ➝ Sector Outperform$12.002/24/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/5/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.001/30/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $16.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,080.85N/AN/A$0.97 per share1.94PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$1.98 per shareN/ASNYRSynergy CHC Corp. (Uplisting)$34.83M0.47N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$22.27M-$0.92N/AN/AN/AN/A-203.91%-128.05%5/13/2025 (Estimated)PEPGPepGen-$78.63M-$2.84N/AN/AN/AN/A-60.17%-48.88%5/13/2025 (Estimated)QNCXQuince Therapeutics-$31.39M-$1.31N/AN/AN/AN/A-53.27%-22.73%5/12/2025 (Estimated)SNYRSynergy CHC Corp. (Uplisting)N/AN/A0.003.22N/AN/AN/AN/AN/ALatest SNYR, PEPG, GANX, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GANXGain Therapeutics-$0.16N/AN/AN/AN/AN/A5/13/2025Q1 2025PEPGPepGen-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025QNCXQuince Therapeutics-$0.24N/AN/AN/AN/AN/A3/31/2025Q4 2024SNYRSynergy CHC Corp. (Uplisting)$0.10$0.01-$0.09$0.01$10.55 million$10.30 million3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/A3/24/2025Q4 2024QNCXQuince Therapeutics-$0.19-$0.28-$0.09-$0.28N/A$0.17 million2/24/2025Q4 2024PEPGPepGen-$0.81-$0.68+$0.13-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ASNYRSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.042.992.99PEPGPepGenN/A8.478.47QNCXQuince Therapeutics0.339.539.53SNYRSynergy CHC Corp. (Uplisting)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%PEPGPepGen58.01%QNCXQuince Therapeutics30.75%SNYRSynergy CHC Corp. (Uplisting)N/AInsider OwnershipCompanyInsider OwnershipGANXGain Therapeutics11.70%PEPGPepGen4.60%QNCXQuince Therapeutics16.80%SNYRSynergy CHC Corp. (Uplisting)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2028.75 million23.42 millionOptionablePEPGPepGen3032.69 million31.10 millionNot OptionableQNCXQuince Therapeutics6044.12 million36.61 millionOptionableSNYRSynergy CHC Corp. (Uplisting)408.57 millionN/AN/ASNYR, PEPG, GANX, and QNCX HeadlinesRecent News About These CompaniesSynergy CHC Stock Short Interest Report | NASDAQ:SNYR | BenzingaApril 17, 2025 | benzinga.comSynergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | markets.businessinsider.comSynergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call InformationMarch 21, 2025 | markets.businessinsider.comRoth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy RecommendationJanuary 22, 2025 | msn.comSynergy CHC Announces 7th Quarter of ProfitabilityDecember 7, 2024 | markets.businessinsider.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in StockOctober 25, 2024 | insidertrades.comSynergy CHC Corp. Announces Closing of Initial Public OfferingOctober 24, 2024 | globenewswire.comSynergy CHC Corp. Prices $10.35 Million Initial Public OfferingOctober 22, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, PEPG, GANX, and QNCX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.88 -0.03 (-1.57%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$1.90 +0.03 (+1.33%) As of 04/29/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.PepGen NASDAQ:PEPG$1.53 -0.07 (-4.38%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$1.52 -0.02 (-0.98%) As of 04/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Quince Therapeutics NASDAQ:QNCX$1.13 0.00 (-0.26%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$1.12 -0.01 (-0.80%) As of 04/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Synergy CHC Corp. (Uplisting) NASDAQ:SNYR$1.90 -0.02 (-1.04%) As of 04/29/2025 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
